Treatment of atypical nevi with imiquimod 5% cream

Archives of Dermatology

Volumn 143, Issue 3, 2007, Pages 379-385

  Somani, Najwa ^a   Martinka, Magdalena ^a   Crawford, Richard I ^a   Dutz, Jan P ^a   Rivers, Jason K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD;

ADULT; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CREAM; DYSPLASTIC NEVUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY;

ADULT; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; DOSAGE FORMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEVUS;

EID: 33947533636     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.3.379     Document Type: Article

References (34)

1. Carey WP Jr, Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer. 1994;74:3118-3125.
2. Burden AD, Newell J, Andrew N, Kavanagh G, Connor JM, MacKie RM. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol. 1999;135:261-265.
3. Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol. 1995;33:1000-1007.
4. Broberg A, Augustsson A. Atopic dermatitis and melanocytic nevi. Br J Dermatol. 2000;142:306-309.
5. Synnerstad I, Nilsson L, Fredrikson M, Rosdahl I. Fewer melanocytic nevi found in children with active atopic dermatitis than in children without dermatitis. Arch Dermatol. 2004;140:1471-1475.
6. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumour necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol. 1991;96:180-185.
7. Bennett C, Copeman PW. Melanocyte mutation in halo naevus and malignant melanoma? Br J Dermatol. 1979;100:423-426.
8. Tokura Y, Yamanaka K, Wakita H, et al. Halo congenital nevus undergoing spontaneous regression: involvement of T-cell immunity in involution and presence of circulating anti-nevus cell IgM antibodies. Arch Dermatol. 1994;130:1036-1041.
9. Zeff RA, Freitag A, Grin CM, Grant-Kels JM. The immune response in halo nevi. J Am Acad Dermatol. 1997;37:620-624.
10. Bayer-Garner IB, Ivan D, Schwartz MR, Tschen JA. The immunopathology of regression in benign lichenoid keratosis, keratoacanthoma and halo nevus. Clin Med Res. 2004;2:89-97.
11. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139:1347-1350.
12. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14.
13. Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol. 2005;141:510-514.
14. Kamin A, Eigentler TK, Radny P, Bauer J, Weide B, Garbe C. Imiquimod in the treatment of extensive recurrent lentigo maligna. J Am Acad Dermatol. 2005;52:51-52.
15. Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg. 2004;30:1543-1545.
16. Kupfer-Bessaguet I, Guillet G, Misery L, Carre JL, Leroy JP, Sassolas B. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. J Am Acad Dermatol. 2004;51:635-639.
17. Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol. 2004;151:485-488.
18. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29:15-21.
19. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149:66-70.
20. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843-845.
21. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol. 2004;173:3051-3061.
22. Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, Braathen LR. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004;151:903-906.
23. Schon MP, Wienrich BG, Drewniok C, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol. 2004;122:1266-1276.
24. Hesling C, D'Incan M, Mansard S, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol. 2004;150:761-767.
25. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205:135-138.
26. Ugurel S, Wagner A, Pfohler C, Tilgen W, Reinhold U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol. 2002;147:621-624.
27. Owens ML, Tygum KI, Senta TA, Myers JA, Fox TL, Smith MH. A safety assessment of topical imiquimod. In: Program and abstracts of the 19th World Congress of Dermatology; June 15-21, 1997; Sydney, Australia.
28. Brown T, Zirvi M, Cotsarelis G, Gelfand JM. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52:715-716.
29. Francois C, Bernard I, Castelain S, et al. Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation. Antimicrob Agents Chemother. 2005;49:3770-3775.
30. Gilli F, Marnetto F, Caldano M, et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler. 2006;12:47-57.
31. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology. 2003;61:S24-S26.
32. Wenzel J, Uerlich M, Haller O, et al. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol. 2005;32:257-262.
33. Wenzel J, Bekisch B, Uerlich M, Haller O, Bieber T, Tueting T. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol. 2005;124:37-48.
34. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol. 2006;5:56-62.